InterMune® announces support for first ever European Patient Charter on idiopathic pulmonary fibrosis (IPF)

To mark international Rare Disease Day, InterMune has announced its support for the development of a European Patient Charter for people with idiopathic pulmonary fibrosis (IPF). IPF is an irreversible, progressive and ultimately fatal fibrotic interstitial lung disease,. IPF has a projected survival rate of only 20-40% after five years1, 2 making it more rapidly lethal than many cancers3, 4. The disease causes scarring of the lungs, irreversibly destroying normal lung architecture and hindering a person's ability to breathe.
Source: Health News from Medical News Today - Category: Consumer Health News Tags: Respiratory / Asthma Source Type: news